Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
K+S Raises 2026 Earnings Outlook After Strong Q1 Results 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Roche is buying Genmark Diagnostics for $1.8 billion or €1.5 billion, and this was revealed on Monday, March 15. The price is for the full acquisition of the US-based molecular diagnostic tests maker.
The numbers in Roche’s newest investment
Roche’s price offer is equivalent to the price of $24.05 per share in an all-cash deal. This also showed a premium of 43% on GenMark’s closing stock on Feb. 10, just before the speculations about Roche’s plans to purchase GenMark made rounds, as per CNBC.
The Swiss pharmaceuticals manufacturer company decided to buy the leading provider of multiplex molecular diagnostic solutions so it can expand the business and make its presence in the diagnostics sector.
“Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against infectious diseases,” Thomas Schinecker, Roche’s chief executive officer, said via press release.
It was added that the acquisition that was approved by the respective board of directors of Roche and GenMark Diagnostics is expected to be completed within the second quarter of 2021. Once the negotiations are done, the latter’s main operations will not be moved but will continue in its current office location in Carlsbad, California.
The setup in the merger deal
The terms in the merger agreement were partly disclosed, and one clause states that Roche will immediately and directly initiate a tender offer to purchase all outstanding stocks of GenMark’s shares.
At any rate, GenMark’s portfolio will complement and further enhance Roche’s molecular diagnostics portfolio. It is also expected that the Swiss company will widen its global network reach when it starts to distribute GenMark’s items and products.
“As a part of Roche, we can accelerate our mission to enable rapid diagnosis of infectious disease to improve patient outcomes,” CEO of GenMark Diagnostics, Scott Mendel, said. “Together with Roche’s diagnostics healthcare solutions, we will be able to provide a full suite of molecular diagnostic solutions to customers around the world.”
Finally, Mendel added that GenMark is thrilled to become part of the globally known Roche. He is confident that they made the right decision to move forward with the Swiss firm.
